Nifty
Sensex
:
:
10656.20
35474.51
-107.20 (-1.00%)
-300.37 (-0.84%)

Pharmaceuticals & Drugs

Rating :
62/99

BSE: 506943 | NSE: JBCHEPHARM

306.15
-3.35 (-1.08%)
20-Nov-2018 | 3:52PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  309.50
  •  309.50
  •  304.20
  •  309.50
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  14745
  •  45.14
  •  352.30
  •  239.95

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 2,462.86
  • 16.48
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 2,462.23
  • 0.65%
  • 1.62

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 55.81%
  • 3.32%
  • 20.21%
  • FII
  • DII
  • Others
  • 0.02%
  • 11.84%
  • 8.80%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 5.67
  • 5.58
  • 2.51

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 5.21
  • 3.86
  • -3.78

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 4.98
  • 13.34
  • -10.61

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.26
  • 16.64
  • 16.27

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 1.45
  • 1.79
  • 1.94

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 7.77
  • 9.40
  • 10.06

Quarterly Results

Standalone Figures in Rs. Crores /

Consolidated
Description
Jun 18
Jun 17
Var%
Mar 18
Mar 17
Var%
Dec 17
Dec 16
Var%
Sep 17
Sep 16
Var%
Net Sales
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
EBITDA
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
EBIDTM
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
Other Income
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Depreciation
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PBT
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PAT
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PATM
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
EPS
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Net Sales
-
1,414.30
1,368.32
1,231.58
1,144.21
1,021.86
866.13
801.87
890.79
756.88
717.09
Net Sales Growth
-
3.36%
11.10%
7.64%
11.97%
17.98%
8.01%
-9.98%
17.69%
5.55%
 
Cost Of Goods Sold
-
542.41
552.00
491.41
341.40
413.95
371.52
320.07
277.04
178.72
187.62
Gross Profit
-
871.88
816.32
740.17
802.81
607.92
494.60
481.80
613.75
578.17
529.48
GP Margin
-
61.65%
59.66%
60.10%
70.16%
59.49%
57.10%
60.08%
68.90%
76.39%
73.84%
Total Expenditure
-
1,196.46
1,135.93
1,025.55
964.09
873.67
760.48
701.55
698.43
589.89
660.24
Power & Fuel Cost
-
58.28
54.89
55.28
53.02
46.61
39.75
29.89
23.34
18.04
15.97
% Of Sales
-
4.12%
4.01%
4.49%
4.63%
4.56%
4.59%
3.73%
2.62%
2.38%
2.23%
Employee Cost
-
251.10
217.34
175.31
159.56
143.67
130.05
112.66
124.93
91.71
87.82
% Of Sales
-
17.75%
15.88%
14.23%
13.94%
14.06%
15.02%
14.05%
14.02%
12.12%
12.25%
Manufacturing Exp.
-
139.83
131.45
119.35
223.53
102.44
61.75
52.97
60.85
102.74
108.00
% Of Sales
-
9.89%
9.61%
9.69%
19.54%
10.02%
7.13%
6.61%
6.83%
13.57%
15.06%
General & Admin Exp.
-
53.96
42.26
34.82
32.46
31.69
27.94
31.31
38.21
46.25
38.44
% Of Sales
-
3.82%
3.09%
2.83%
2.84%
3.10%
3.23%
3.90%
4.29%
6.11%
5.36%
Selling & Distn. Exp.
-
87.44
78.27
72.72
75.13
73.59
56.04
68.65
131.60
110.03
103.83
% Of Sales
-
6.18%
5.72%
5.90%
6.57%
7.20%
6.47%
8.56%
14.77%
14.54%
14.48%
Miscellaneous Exp.
-
63.43
59.72
76.65
79.01
61.72
73.44
86.00
42.47
42.41
103.83
% Of Sales
-
4.48%
4.36%
6.22%
6.91%
6.04%
8.48%
10.72%
4.77%
5.60%
16.53%
EBITDA
-
217.84
232.39
206.03
180.12
148.19
105.65
100.32
192.36
166.99
56.85
EBITDA Margin
-
15.40%
16.98%
16.73%
15.74%
14.50%
12.20%
12.51%
21.59%
22.06%
7.93%
Other Income
-
36.58
50.16
56.65
10.89
37.70
27.87
28.98
6.16
14.21
15.80
Interest
-
3.49
5.37
10.65
6.82
5.93
5.28
24.03
10.49
11.57
15.17
Depreciation
-
56.97
47.22
41.22
38.64
28.02
24.66
22.42
22.79
21.57
20.43
PBT
-
193.95
229.94
210.82
145.55
151.94
103.57
82.85
165.24
148.07
37.06
Tax
-
55.23
45.55
49.58
45.14
25.95
24.13
165.53
25.92
29.32
11.35
Tax Rate
-
28.48%
19.81%
23.52%
31.01%
29.68%
23.30%
19.63%
15.69%
19.80%
30.63%
PAT
-
138.34
184.06
161.14
100.41
61.50
79.44
677.91
139.32
118.75
25.71
PAT before Minority Interest
-
138.72
184.40
161.24
100.41
61.50
79.44
677.91
139.32
118.75
25.71
Minority Interest
-
-0.38
-0.34
-0.10
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
-
9.78%
13.45%
13.08%
8.78%
6.02%
9.17%
84.54%
15.64%
15.69%
3.59%
PAT Growth
-
-24.84%
14.22%
60.48%
63.27%
-22.58%
-88.28%
386.58%
17.32%
361.88%
 
Unadjusted EPS
-
16.48
21.70
19.14
11.84
7.26
9.38
80.11
16.50
14.08
3.05

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Shareholder's Funds
1,441.56
1,363.67
1,183.84
994.87
1,042.81
1,020.27
969.95
691.54
568.12
468.89
Share Capital
16.71
16.96
16.96
16.96
16.95
16.94
16.94
16.90
16.87
16.87
Total Reserves
1,424.84
1,346.70
1,166.87
977.91
1,025.82
1,003.22
952.83
674.31
550.81
451.58
Non-Current Liabilities
45.66
26.98
31.02
32.62
31.93
40.45
39.52
36.50
152.63
191.61
Secured Loans
0.00
0.00
0.00
0.00
0.09
0.22
0.40
0.54
98.49
134.30
Unsecured Loans
0.00
0.00
0.00
0.40
0.40
7.03
12.14
11.99
38.29
44.47
Long Term Provisions
9.67
12.56
10.43
12.03
12.19
8.23
8.27
7.71
0.00
0.00
Current Liabilities
736.28
693.46
797.22
459.75
276.27
239.48
188.32
271.33
116.55
85.81
Trade Payables
110.39
98.98
90.85
77.51
60.75
60.51
37.09
50.21
43.28
34.55
Other Current Liabilities
119.53
122.15
138.73
103.74
98.06
101.15
78.75
61.22
39.53
30.10
Short Term Borrowings
29.29
48.86
193.02
126.88
81.71
37.28
55.23
133.36
0.00
0.00
Short Term Provisions
477.06
423.47
374.61
151.62
35.76
40.54
17.26
26.54
33.74
21.16
Total Liabilities
2,226.27
2,086.29
2,013.75
1,487.24
1,351.01
1,300.20
1,197.79
999.37
837.30
746.31
Net Block
639.50
679.44
440.22
328.56
310.55
334.41
276.31
258.39
246.78
246.71
Gross Block
1,053.76
1,038.55
753.75
601.67
540.54
537.46
456.51
420.25
386.67
366.57
Accumulated Depreciation
414.25
359.10
313.53
273.11
229.99
203.06
180.19
161.85
139.89
119.86
Non Current Assets
717.89
879.15
831.58
586.31
370.37
356.49
331.58
278.78
271.13
260.89
Capital Work in Progress
17.40
3.76
134.89
55.17
46.36
4.81
39.00
3.75
0.08
6.69
Non Current Investment
49.96
185.84
231.42
184.83
2.75
2.99
3.00
3.94
24.27
7.49
Long Term Loans & Adv.
10.15
9.43
22.63
17.74
10.71
14.28
13.27
12.70
0.00
0.00
Other Non Current Assets
0.88
0.67
2.43
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Current Assets
1,508.38
1,207.14
1,182.16
900.94
980.65
943.71
866.22
720.60
566.17
485.42
Current Investments
383.77
224.96
247.28
366.78
497.26
394.68
298.92
81.05
0.00
0.00
Inventories
213.73
200.17
187.98
150.27
134.40
104.53
101.03
111.67
83.81
80.77
Sundry Debtors
300.73
265.97
272.64
262.35
235.51
191.27
136.05
345.58
344.82
302.80
Cash & Bank
29.92
13.39
12.90
25.19
11.81
156.23
219.53
126.89
77.86
43.85
Other Current Assets
580.23
14.36
2.51
0.38
101.68
96.99
110.69
55.41
59.68
58.00
Short Term Loans & Adv.
568.86
488.30
458.83
95.97
101.48
96.84
110.29
54.66
59.58
57.87
Net Current Assets
772.10
513.68
384.94
441.19
704.37
704.23
677.90
449.27
449.62
399.61
Total Assets
2,226.27
2,086.29
2,013.74
1,487.25
1,351.02
1,300.20
1,197.80
999.38
837.30
746.31

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Cash From Operating Activity
123.05
201.13
140.41
126.66
-13.98
84.20
879.69
133.92
121.97
91.11
PBT
193.95
229.94
212.23
145.55
87.44
103.57
843.44
165.34
148.07
37.06
Adjustment
17.79
13.11
-1.40
38.51
20.75
-4.40
33.13
16.60
25.01
63.44
Changes in Working Capital
-47.83
5.92
-16.96
-19.52
-93.71
9.47
167.35
-15.87
-22.77
1.75
Cash after chg. in Working capital
163.91
248.97
193.88
164.53
14.49
108.65
1,043.91
166.07
150.31
102.25
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-40.87
-47.84
-53.47
-37.87
-28.47
-24.45
-164.22
-32.15
-28.33
-11.14
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-20.81
-45.31
-27.62
-111.89
-142.50
-116.05
-260.92
-89.46
-29.46
-14.31
Net Fixed Assets
-29.56
-152.86
-187.76
-69.64
-55.43
-41.77
-69.55
-32.72
-10.92
-13.11
Net Investments
-22.92
67.89
-14.16
-61.38
-102.46
-95.95
-214.42
-60.83
-16.87
-2.68
Others
31.67
39.66
174.30
19.13
15.39
21.67
23.05
4.09
-1.67
1.48
Cash from Financing Activity
-59.52
-183.84
-99.62
-1.39
12.04
-31.45
-526.12
4.56
-58.49
-47.91
Net Cash Inflow / Outflow
42.72
-28.02
13.17
13.38
-144.43
-63.30
92.65
49.02
34.02
28.88
Opening Cash & Equivalents
-21.47
6.54
-5.46
11.81
156.23
219.53
126.89
77.86
43.85
14.96
Closing Cash & Equivalent
21.24
-21.47
9.42
25.19
11.81
156.23
219.53
126.89
77.86
43.85

Financial Ratios

Consolidated /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Book Value (Rs.)
172.50
160.77
139.57
117.31
123.07
119.21
113.34
80.86
66.82
55.35
ROA
6.43%
8.99%
9.21%
7.08%
4.64%
6.36%
61.71%
15.17%
15.00%
3.46%
ROE
9.89%
14.48%
14.80%
9.86%
5.99%
8.07%
82.49%
22.35%
23.05%
5.60%
ROCE
13.70%
16.87%
17.72%
13.49%
8.50%
10.41%
92.09%
22.63%
23.71%
8.07%
Fixed Asset Turnover
1.35
1.53
1.82
2.03
1.92
1.76
1.85
2.22
2.03
2.00
Receivable days
73.13
71.84
79.28
78.41
75.30
68.16
108.62
140.48
154.96
157.34
Inventory Days
53.41
51.77
50.12
44.83
42.16
42.80
47.97
39.77
39.38
39.12
Payable days
33.66
32.86
32.45
27.82
26.91
26.15
26.89
25.89
27.07
26.89
Cash Conversion Cycle
92.88
90.75
96.95
95.43
90.54
84.81
129.69
154.35
167.27
169.57
Total Debt/Equity
0.02
0.04
0.16
0.13
0.09
0.05
0.07
0.25
0.24
0.38
Interest Cover
56.54
43.81
20.80
22.33
15.74
20.61
36.10
16.75
13.80
3.44

News Update:


  • JB Chemicals gets USFDA’s nod for Midodrine Hydrochloride Tablets
    5th Nov 2018, 14:11 PM

    The company plans to commercialize this product in Q1 of next financial year and is expected to boost company's US sales

    Read More
  • JB Chem & Pharma - Quarterly Results
    2nd Nov 2018, 14:53 PM

    Read More
  • USFDA issues four minor observations to JB Chemicals’ Gujarat facility
    19th Oct 2018, 12:37 PM

    The company went through a USFDA pre-approval inspection (PAI) for ANDA filed for a capsule product

    Read More
  • USFDA completes inspection at JB Chemicals’ Gujarat facility
    27th Aug 2018, 10:56 AM

    The said inspection was carried out from August 20, 2018 to August 24, 2018

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.